NASDAQ:SLDB Solid Biosciences (SLDB) Stock Price, News & Analysis $7.14 -0.08 (-1.11%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$7.15 +0.01 (+0.11%) As of 06/12/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Solid Biosciences Stock (NASDAQ:SLDB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Solid Biosciences alerts:Sign Up Key Stats Today's Range$7.12▼$7.4550-Day Range$6.08▼$8.6352-Week Range$3.79▼$8.87Volume1.66 million shsAverage Volume1.11 million shsMarket Capitalization$702.93 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingModerate Buy Company Overview Solid Biosciences Inc. is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein. Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector. In addition to SGT‐001, the company is advancing next-generation programs including SGT-003, a CRISPR/Cas9‐based gene editing approach aimed at correcting specific dystrophin gene mutations, and proprietary assays for sensitive detection of dystrophin expression in muscle tissue. Founded in 2015 and headquartered in Cambridge, Massachusetts, Solid Biosciences leverages partnerships with academic institutions and patient advocacy groups to support clinical development and expand its understanding of DMD biology. Its clinical studies have been conducted at sites across the United States and Europe, reflecting the global nature of DMD research and the need for broad patient enrollment in rare-disease trials. Under the leadership of Chief Executive Officer Ilan Ganot, Solid Biosciences maintains a network of research and manufacturing collaborations to enhance vector production and assay development. The company’s mission remains to deliver transformative therapies to DMD patients by advancing innovative genetic medicines and building the infrastructure required for efficient clinical translation.AI Generated. May Contain Errors. Read More Solid Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreSLDB MarketRank™: Solid Biosciences scored higher than 50% of companies evaluated by MarketBeat, and ranked 597th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingSolid Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSolid Biosciences has a consensus price target of $17.00, representing about 138.1% upside from its current price of $7.14.Amount of Analyst CoverageSolid Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Solid Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Solid Biosciences are expected to decrease in the coming year, from ($1.90) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Solid Biosciences is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Solid Biosciences is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSolid Biosciences has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Solid Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.02% of the float of Solid Biosciences has been sold short.Short Interest Ratio / Days to CoverSolid Biosciences has a short interest ratio ("days to cover") of 9.38.Change versus previous monthShort interest in Solid Biosciences has recently increased by 5.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSolid Biosciences does not currently pay a dividend.Dividend GrowthSolid Biosciences does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.73 News SentimentSolid Biosciences has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Solid Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for SLDB on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat Follows3 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Solid Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders2.66% of the stock of Solid Biosciences is held by insiders.Percentage Held by Institutions81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Solid Biosciences' insider trading history. Receive SLDB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLDB Stock News HeadlinesSolid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comSolid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 6, 2026 | americanbankingnews.comSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page. | Weiss Ratings (Ad)Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comSolid Biosciences to Participate at Upcoming Investor ConferencesJune 1, 2026 | globenewswire.comJ.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)May 24, 2026 | theglobeandmail.comWhere Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?May 20, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)May 14, 2026 | theglobeandmail.comSee More Headlines SLDB Stock Analysis - Frequently Asked Questions How have SLDB shares performed this year? Solid Biosciences' stock was trading at $5.64 at the start of the year. Since then, SLDB stock has increased by 26.6% and is now trading at $7.14. How were Solid Biosciences' earnings last quarter? Solid Biosciences Inc. (NASDAQ:SLDB) released its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.12. When did Solid Biosciences' stock split? Solid Biosciences shares reverse split before market open on Friday, October 28th 2022.The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Solid Biosciences IPO? Solid Biosciences (SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers. Who are Solid Biosciences' major shareholders? Solid Biosciences' top institutional shareholders include Perceptive Advisors LLC (12.09%), Janus Henderson Group PLC (4.07%), Redmile Group LLC (2.04%) and Monashee Investment Management LLC (1.44%). Insiders that own company stock include Perceptive Advisors Llc, Alexander Cumbo, David T Howton, Kevin Tan, Gabriel Brooks, Jessie Hanrahan, Paul Herzich, Ilan Ganot and Clare Kahn. View institutional ownership trends. How do I buy shares of Solid Biosciences? Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Solid Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Solid Biosciences investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/12/2026Today6/13/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 SLDB's financial health is in the Green zone, according to TradeSmith. SLDB has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLDB CIK1707502 Webwww.solidbio.com Phone(617) 337-4680FaxN/AEmployees100Year Founded2013Price Target and Rating Average Price Target for Solid Biosciences$17.00 High Price Target$26.00 Low Price Target$9.00 Potential Upside/Downside+138.1%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$174.32 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.42% Return on Assets-61.13% Debt Debt-to-Equity RatioN/A Current Ratio13.10 Quick Ratio13.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book3.13Miscellaneous Outstanding Shares98,450,000Free Float95,831,000Market Cap$702.93 million OptionableOptionable Beta2.43 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:SLDB) was last updated on 6/14/2026 by MarketBeat.com Staff. From Our PartnersIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...Stansberry Research | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | SponsoredJon Najarian's Shocking "Beyond SpaceX" PredictionJon Najarian spent 16 years on CNBC's Fast Money, calling Apple in 2010, Tesla in 2014, and Palantir in 2020. ...Banyan Hill Publishing | SponsoredThe S-1 disclosure Wall Street is racing to traceWhen SpaceX filed its S-1, the SEC required full disclosure of costs - and power consumption for 1 million GPU...Behind the Markets | SponsoredBUY THIS: Claim a backdoor stake in SpaceXThere may be a way to claim pre-IPO exposure to SpaceX before it ever hits public markets - using a simple tra...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
